News Focus
News Focus
icon url

biotech_researcher

09/28/16 7:00 PM

#204709 RE: DewDiligence #204697

"ENTA starts phase-1 trial of NASH compound, EDP-305:"

Dew, 100% owned by ENTA at this point??
icon url

DewDiligence

11/11/16 8:54 AM

#205938 RE: DewDiligence #204697

ENTA presents preclinical data for NASH compound, EDP-305 at AASLD; there are five poster presentations:

http://finance.yahoo.com/news/enanta-announces-data-fxr-agonist-130100913.html

EDP-305 is wholly owned by ENTA. Please see #msg-125454754 for related info.
icon url

DewDiligence

01/04/17 9:14 AM

#207548 RE: DewDiligence #204697

ENTA’s EDP-305 for NASH gets FDA Fast Track designation:

http://finance.yahoo.com/news/fda-grants-fast-track-designation-123000438.html

Fast Track (as opposed to BTD) means essentially nothing; however, this announcement may open some eyes to the fact that ENTA is not just a HCV company, but rather has a potentially valuable NASH program.

See #msg-125454754 for related info.